After graduating from Pavia (Italy) medical school in 2015 with a thesis on Pediatric Hematology/Oncology, Dr. Gurnari completed his training in Hematology at the University of Rome, Tor Vergata. He then decided to continue his education at Tor Vergata, where he obtained a Ph.D in "Immunology, Molecular Medicine and Applied Biotechnology". Simultaneously, Dr. Gurnari has spent the last 5 years collaborating with the Department of Translational Hematology and Oncology Research of Cleveland Clinic (USA) where he has been focusing on the genomics of bone marrow failure disorders and myeloid neoplasia. His clinical and translational research expertise encompasses myeloid malignancies with a special focus on acute promyelocytic leukemia, myelodysplastic syndromes, VEXAS, and acute myeloid leukemia. Dr. Gurnari is a member of the European Hematology Association (EHA) for which serves as a Mentor of the Classical Master Class Program, and of the European Society for Blood and Marrow Transplantation (EBMT), and he is actively involved in the activities of the Trainee Committee. He is also a member of other national and international societies such as the American Association for the Advancement of Science, the Italian Hematology Association and the International Paroxysmal Nocturnal Hemoglobinuria Interest Group. In these years, Dr. Gurnari has been awarded several international prizes such as the Tito Bastianello Young Investigator Award in MDS research and the ASH-IPIG Award for PNH research (2020 and 2022). At this link you can find a comlete list of his publications: https://pubmed.ncbi.nlm.nih.gov/?term=Gurnari+C&sort=date